High altitude periodic breathing
Methodology & AI Transparency ⓘ
High altitude periodic breathing Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Insomnia, Sleep Apnea & Sleep Health diagnostic criteria (G47.32), workup for High altitude periodic breathing integrates CBT-I behavioral sleep in High altitude periodic breathing (G47.32: efficiency tracking) with evidence-graded therapy tailored to Nocturnal Oxygen Saturation in High altitude periodic breathing (G47.32: (SpO2)) response.
- 2 Real-world patient consensus: Mapped to Insomnia, Sleep Apnea & Sleep Health under ICD-10-CM G47.32 for High altitude periodic breathing clinical workups.
- 3 Typical cash cost range: Differential triage of High altitude periodic breathing (G47.32) utilizes CBT-I behavioral sleep in High altitude periodic breathing (G47.32: efficiency tracking).
- 4 Top reported side effects / signs: Longitudinal High altitude periodic breathing monitoring tracks Nocturnal Oxygen Saturation in High altitude periodic breathing (G47.32: (SpO2)) toward >= 94% nadir > 90% (G47.32).
Ask our AI Specialists anything about High altitude periodic breathing
What Is High altitude periodic breathing?
Under Insomnia, Sleep Apnea & Sleep Health diagnostic criteria (G47.32), workup for High altitude periodic breathing integrates CBT-I behavioral sleep in High altitude periodic breathing (G47.32: efficiency tracking) with evidence-graded therapy tailored to Nocturnal Oxygen Saturation in High altitude periodic breathing (G47.32: (SpO2)) response.
Pathophysiology, Underlying Causes & Clinical Presentation
In High altitude periodic breathing (G47.32), physiological disruption stems from or upper-airway pharyngeal in High altitude periodic breathing (G47.32: collapse during REM), informing Insomnia, Sleep Apnea & Sleep Health protocols that track Serum Ferritin (Restless in High altitude periodic breathing (G47.32: Legs)) (> 75 ng/mL (G47.32)).
Common Symptoms & Clinical Signs
- • Presentation of High altitude periodic breathing (G47.32): loud habitual snoring, in High altitude periodic breathing (G47.32: witnessed breathing pauses,)
- • Secondary High altitude periodic breathing clinical sign: daytime microsleeps, cognitive in High altitude periodic breathing (G47.32: brain fog, or)
- • Symptom flares in High altitude periodic breathing correlating with Nocturnal Oxygen Saturation in High altitude periodic breathing (G47.32: (SpO2)) deviation outside >= 94% nadir > 90% (G47.32)
- • Functional sleep disorders impact requiring CBT-I behavioral sleep in High altitude periodic breathing (G47.32: efficiency tracking) evaluation (G47.32)
High altitude periodic breathing Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G47.32 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Insomnia, Sleep Apnea & Sleep Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Nocturnal Oxygen Saturation in High altitude periodic breathing (G47.32: (SpO2)) | >= 94% nadir > 90% (G47.32) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin (Restless in High altitude periodic breathing (G47.32: Legs)) | > 75 ng/mL (G47.32) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Apnea-Hypopnea Index (AHI) [High altitude periodic breathing G47.32] | < 5 events/hour (G47.32) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for High altitude periodic breathing
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Rilonacept Arcalyst • RxCUI 763453 | FDA Prescription Therapeutic Agent | 77% | $0.4800 | $ 27.94 /mo |
| Dichlorphenamide Ormalvi, Keveyis • RxCUI 197594 | Carbonic Anhydrase Inhibitor | 90% | $0.9400 | $ 46.57 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (High altitude periodic breathing)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Achieved blood pressure and heart and blood vessel outcomes in high-risk: What a 8,407-Participant Study Found Mean achieved SBP less than 120 mm Hg during treatment was associated with increased risk of heart and blood vessel outcomes except for heart attack and stroke. Lancet (London, England) • 2017-06-03 • Meta-Analysis | N = 8,407 | 99/100 | PMID 28390695 ↗ |
| New Insights on Major outcomes in high-risk hypertensive patients randomized to: What a 9,048-Participant Study Found Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive. JAMA • 2002-12-18 • Randomized Controlled Trial | N = 9,048 | 96/100 | PMID 12479763 ↗ |
| New Insights on Heart and blood vessel outcomes in high-risk hypertensive patients stratified by: What a 8,126-Participant Study Found Older high-risk patients with high blood pressure and reduced GFR are more likely to develop CHD than to develop ESRD. Annals of internal medicine • 2006-02-07 • Randomized Controlled Trial | N = 8,126 | 96/100 | PMID 16461961 ↗ |
| New Insights on Glucose levels predict hospitalization for congestive heart failure in patients: What a 25,620-Participant Study Found Fasting plasma glucose is an independent predictor of hospitalization for CHF in high-risk subjects. Circulation • 2007-03-20 • Randomized Controlled Trial | N = 25,620 | 96/100 | PMID 17339550 ↗ |
| New Insights on Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin: What a 2,067-Participant Study Found Evolocumab reduced LDL-C levels by 66% (95% CI, 58% to 73%) to 75% (95% CI, 65% to 84%) (every 2 weeks) and by 63% (95% CI, 54% to 71%) to 75% (95% CI, 67% to 83%) (monthly) vs placebo at the mean of weeks 10 and 12 in the... JAMA • 2014-05-14 • Phase III Randomized Trial | N = 2,067 | 96/100 | PMID 24825642 ↗ |
High altitude periodic breathing Patient Community & “People Like Me” Threads
Filter High altitude periodic breathing community threads and patient logs by age, biological sex, dosage, and treatment duration.